Xiaoqun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoqun Zhu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Xia Zhou
Department of Neurology The First Affiliated Hospital of Anhui Medical University Hefei China
17 shared publications- Zhongwu Sun
Department of Neurology The First Affiliated Hospital of Anhui Medical University Hefei China
11 shared publications Chaojuan Huang
Department of Neurology The First Affiliated Hospital of Anhui Medical University Hefei China
7 shared publicationsJing Cao
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
7 shared publicationsXianfeng Yu
Department of Neurology The First Affiliated Hospital of Anhui Medical University Hefei China
4 shared publicationsZhiwei Li
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Human Brain Mapping
- Vol. 47 (16)
Association of Perivascular Space Volume in Basal Ganglia Subfields With Cognitive Impairment in Cerebral Small Vessel Disease
Perivascular spaces (PVS) serve as essential elements of the glymphatic pathway, facilitating waste clearance and nutrient transport, and their impairment may underlie cognitive deficits in cerebral small vessel disease (CSVD). Here, we investigated associations between PVS characteristics, potential determinants, and cognitive impairment in CSVD. 132 individuals diagnosed with CSVD and 40 healthy controls (HCs) were recruited to participate in a series of thorough neuropsychological assessments and neuroimaging examinations. PVS volume fraction (VF) was quantified in basal ganglia (BG), thalamus, hippocampus, and white matter (WM) using an automated, multimodal image processing pipeline (Enhanced PVS Contrast, EPC) combined with the Frangi filter for robust segmentation. Partial correlation analyses, adjusted for covariates, were performed. CSVD patients exhibited significantly larger PVS VF in the BG and hippocampus, particularly in caudate and putamen subfields of BG (all p < 0.05). In CSVD group, advancing age correlated with elevated PVS VF in both BG and hippocampus, especially in males (all p FDR < 0.05). A main effect of sex on PVS VF was observed in this patient cohort across the BG, caudate, hippocampus and thalamus, where males exhibited larger PVS VF than females (all p < 0.05). In HC group, age correlated positively with PVS volume fraction in the BG ( p FDR < 0.05), with no significant sex differences across regions. Enlarged BG‐PVS was associated with worse global cognitive function (pr = −0.27, p FDR = 0.027) and processing speed (pr = −0.31, p FDR = 0.010), persisting after controlling for other neuroimaging markers (including WMHs, lacunes, and CMBs) and regional volume. Subfield analyses revealed the correlation mainly occurring in the putamen (pr = −0.31, p FDR = 0.010). Hippocampal PVS VF inversely correlated with hippocampal volume (pr = −0.26, p FDR = 0.043), more pronounced in females, and was significantly linked to worse visuospatial function (pr = −0.33, p FDR = 0.010). Regional PVS enlargement in CSVD, particularly in BG and hippocampus regions, reflects underlying glymphatic impairment related to age and sex. The prominence of this finding within BG subregions further underscores their role in the pathogenesis of neurocognitive decline.
- 9 November 2026
- Published by Wiley in Human Brain Mapping
- Vol. 47 (16)
Open AccessAssociation of Perivascular Space Volume in Basal Ganglia Subfields With Cognitive Impairment in Cerebral Small Vessel Disease
Perivascular spaces (PVS) serve as essential elements of the glymphatic pathway, facilitating waste clearance and nutrient transport, and their impairment may underlie cognitive deficits in cerebral small vessel disease (CSVD). Here, we investigated associations between PVS characteristics, potential determinants, and cognitive impairment in CSVD. 132 individuals diagnosed with CSVD and 40 healthy controls (HCs) were recruited to participate in a series of thorough neuropsychological assessments and neuroimaging examinations. PVS volume fraction (VF) was quantified in basal ganglia (BG), thalamus, hippocampus, and white matter (WM) using an automated, multimodal image processing pipeline (Enhanced PVS Contrast, EPC) combined with the Frangi filter for robust segmentation. Partial correlation analyses, adjusted for covariates, were performed. CSVD patients exhibited significantly larger PVS VF in the BG and hippocampus, particularly in caudate and putamen subfields of BG (all p < 0.05). In CSVD group, advancing age correlated with elevated PVS VF in both BG and hippocampus, especially in males (all p FDR < 0.05). A main effect of sex on PVS VF was observed in this patient cohort across the BG, caudate, hippocampus and thalamus, where males exhibited larger PVS VF than females (all p < 0.05). In HC group, age correlated positively with PVS volume fraction in the BG ( p FDR < 0.05), with no significant sex differences across regions. Enlarged BG‐PVS was associated with worse global cognitive function (pr = −0.27, p FDR = 0.027) and processing speed (pr = −0.31, p FDR = 0.010), persisting after controlling for other neuroimaging markers (including WMHs, lacunes, and CMBs) and regional volume. Subfield analyses revealed the correlation mainly occurring in the putamen (pr = −0.31, p FDR = 0.010). Hippocampal PVS VF inversely correlated with hippocampal volume (pr = −0.26, p FDR = 0.043), more pronounced in females, and was significantly linked to worse visuospatial function (pr = −0.33, p FDR = 0.010). Regional PVS enlargement in CSVD, particularly in BG and hippocampus regions, reflects underlying glymphatic impairment related to age and sex. The prominence of this finding within BG subregions further underscores their role in the pathogenesis of neurocognitive decline.
- Open Access
- 25 September 2026
- Published by Wiley in iNew Medicine
- p. e70074
Bidirectional Pathological Axis Between Alzheimer's Disease and Circadian Rhythm Disturbance: Mechanisms and Therapeutic Strategies
Circadian rhythm disturbance is highly prevalent in patients with Alzheimer's disease (AD) and is consistently associated with more rapid cognitive decline and reduced quality of life. Accumulating evidence supports a bidirectional relationship between circadian rhythm disruption and AD pathology, in which each may reciprocally exacerbate the other. However, whether circadian rhythm disturbance acts as an independent causal driver of AD initiation or primarily as a factor that modifies and accelerates pathology once it is underway remains an open question. This article synthesizes current evidence on the proposed mechanisms linking circadian dysregulation to AD pathophysiology, with particular attention to the suprachiasmatic nucleus (SCN), glymphatic clearance, clock gene networks, and apolipoprotein E ε4 allele (APOE ε4) genotype. Emerging circadian‐targeted interventions, including both pharmacological and nonpharmacological approaches, are also reviewed and their current limitations are discussed. A more complete understanding of this bidirectional axis may help inform future research directions and ultimately contribute to the development of early monitoring and combination treatment strategies for AD.
- 25 September 2026
- Published by Wiley in iNew Medicine
- p. e70074
Open AccessBidirectional Pathological Axis Between Alzheimer's Disease and Circadian Rhythm Disturbance: Mechanisms and Therapeutic Strategies
Circadian rhythm disturbance is highly prevalent in patients with Alzheimer's disease (AD) and is consistently associated with more rapid cognitive decline and reduced quality of life. Accumulating evidence supports a bidirectional relationship between circadian rhythm disruption and AD pathology, in which each may reciprocally exacerbate the other. However, whether circadian rhythm disturbance acts as an independent causal driver of AD initiation or primarily as a factor that modifies and accelerates pathology once it is underway remains an open question. This article synthesizes current evidence on the proposed mechanisms linking circadian dysregulation to AD pathophysiology, with particular attention to the suprachiasmatic nucleus (SCN), glymphatic clearance, clock gene networks, and apolipoprotein E ε4 allele (APOE ε4) genotype. Emerging circadian‐targeted interventions, including both pharmacological and nonpharmacological approaches, are also reviewed and their current limitations are discussed. A more complete understanding of this bidirectional axis may help inform future research directions and ultimately contribute to the development of early monitoring and combination treatment strategies for AD.
- Open Access
- 18 June 2026
- Published by Wolters Kluwer Health in Aging Advances
- Vol. 3 (3) , 97-103
Mediating role of klotho protein in the impact of alcohol consumption on cognitive impairment in older adults: A cross-sectional analysis of NHANES data
JOURNAL/agad/04.03/02274129-202607000-00001/figure1/v/2026-07-06T115155Z/r/image-tiff Objectives: In light of concerns about the link between alcohol consumption and cognitive decline, there is a gap in the literature regarding the role of the Klotho protein in connecting alcohol to dementia. This study aimed to investigate whether serum Klotho protein mediates and/or moderates the association between alcohol consumption and cognitive performance in a nationally representative sample of older U.S. adults from the National Health and Nutrition Examination Survey (NHANES). Methods: This study analyzed cross-sectional information from 1168 participants aged ≥ 60 years derived from the NHANES between 2011 and 2014. The data included demographic, behavioral, and health determinants; details on the occurrence and average daily intake of alcohol consumption; concentrations of serum soluble Klotho protein; and evaluations of cognitive function. We performed both mediation and moderation analyses. Mediation was tested using bootstrapping, and moderation was tested by including a Klotho × alcohol interaction term in weighted linear regression. Results: Compared with females, males not only reported a higher prevalence of alcohol consumption (93.95% vs . 80.56%) but also reported greater mean daily alcohol intake (23.86 ± 41.84 g/day vs . 12.19 ± 23.33 g/day). In contrast, females had higher baseline Klotho levels ( P = 0.012). Both age and alcohol consumption were negatively correlated with Klotho levels, whereas cognition was positively correlated with Klotho levels (all P < 0.05). Importantly, our moderation analysis revealed that the interaction term (KL × Alcohol) was significant (β = –0.89, P < 0.001), indicating that individuals with lower Klotho levels experience a more pronounced negative effect of alcohol on cognition. Furthermore, Klotho concentrations were directly associated with CERAD-WL scores (weighted β [SE] = 0.086 [0.030 to 0.142], P = 0.003), accounting for 10.1% of the linkage between alcohol intake and Klotho-mediated CERAD-WL. Conclusion: In this cross-sectional study, Klotho seemed to moderate the alcohol–cognition association in older adults, with sex differences and a stronger negative link between alcohol and cognition among those with lower Klotho levels.
- 18 June 2026
- Published by Wolters Kluwer Health in Aging Advances
- Vol. 3 (3) , 97-103
Open AccessMediating role of klotho protein in the impact of alcohol consumption on cognitive impairment in older adults: A cross-sectional analysis of NHANES data
JOURNAL/agad/04.03/02274129-202607000-00001/figure1/v/2026-07-06T115155Z/r/image-tiff Objectives: In light of concerns about the link between alcohol consumption and cognitive decline, there is a gap in the literature regarding the role of the Klotho protein in connecting alcohol to dementia. This study aimed to investigate whether serum Klotho protein mediates and/or moderates the association between alcohol consumption and cognitive performance in a nationally representative sample of older U.S. adults from the National Health and Nutrition Examination Survey (NHANES). Methods: This study analyzed cross-sectional information from 1168 participants aged ≥ 60 years derived from the NHANES between 2011 and 2014. The data included demographic, behavioral, and health determinants; details on the occurrence and average daily intake of alcohol consumption; concentrations of serum soluble Klotho protein; and evaluations of cognitive function. We performed both mediation and moderation analyses. Mediation was tested using bootstrapping, and moderation was tested by including a Klotho × alcohol interaction term in weighted linear regression. Results: Compared with females, males not only reported a higher prevalence of alcohol consumption (93.95% vs . 80.56%) but also reported greater mean daily alcohol intake (23.86 ± 41.84 g/day vs . 12.19 ± 23.33 g/day). In contrast, females had higher baseline Klotho levels ( P = 0.012). Both age and alcohol consumption were negatively correlated with Klotho levels, whereas cognition was positively correlated with Klotho levels (all P < 0.05). Importantly, our moderation analysis revealed that the interaction term (KL × Alcohol) was significant (β = –0.89, P < 0.001), indicating that individuals with lower Klotho levels experience a more pronounced negative effect of alcohol on cognition. Furthermore, Klotho concentrations were directly associated with CERAD-WL scores (weighted β [SE] = 0.086 [0.030 to 0.142], P = 0.003), accounting for 10.1% of the linkage between alcohol intake and Klotho-mediated CERAD-WL. Conclusion: In this cross-sectional study, Klotho seemed to moderate the alcohol–cognition association in older adults, with sex differences and a stronger negative link between alcohol and cognition among those with lower Klotho levels.
- Open Access
- 14 June 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 227, 107478
DTI-ALPS alterations in cerebral small vessel disease: Associations with executive deficits and gait disorders via white matter injury
- 14 June 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 227, 107478
Open AccessDTI-ALPS alterations in cerebral small vessel disease: Associations with executive deficits and gait disorders via white matter injury
- Open Access
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1779257
Association between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer’s disease
Introduction: Dysfunction in both one-carbon metabolism (OCM) and the glymphatic system has been implicated in the pathogenesis of Alzheimer’s disease (AD). However, the potential interrelationship remains poorly understood. This study aimed to investigate the association between OCM biomarkers and glymphatic function in AD and explore their combined effects on cognition. Methods: A total of 210 participants were enrolled, including 68 with normal cognition (NC), 75 with mild cognitive impairment due to AD (AD-MCI), and 67 with dementia due to AD (AD-D). Circulating OCM biomarkers were measured, including serum folate, vitamin B12, and homocysteine levels. Glymphatic-related function was evaluated using the diffusion tensor imaging-analysis along the perivascular space (DTI-ALPS) index, and comprehensive neuropsychological assessments were performed. Results: Serum folate levels ( p = 0.020) and DTI-ALPS index ( p < 0.001) differed significantly between NC and AD groups, with more pronounced differences among female ( p = 0.005; 0.001) and late-life ( p = 0.046; 0.021) subgroups. In AD patients, folate levels were positively correlated with DTI-ALPS index ( r = 0.212, p FDR = 0.032), and both were associated with domain-specific cognitive performance. The low-risk group (high folate and high DTI-ALPS index) outperformed the high-risk group in memory ( p = 0.001) and processing speed ( p = 0.005), and showed higher MMSE ( p = 0.021) and memory scores ( p = 0.003) than the moderate-risk group. Conclusion: Lower serum folate levels and reduced DTI-ALPS index were associated with poorer cognitive performance in AD. Their co-occurrence was linked to worse cognitive outcomes. These findings suggest a potential association between metabolic status and glymphatic function in AD, which requires confirmation in longitudinal studies.
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1779257
Open AccessAssociation between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer’s disease
Introduction: Dysfunction in both one-carbon metabolism (OCM) and the glymphatic system has been implicated in the pathogenesis of Alzheimer’s disease (AD). However, the potential interrelationship remains poorly understood. This study aimed to investigate the association between OCM biomarkers and glymphatic function in AD and explore their combined effects on cognition. Methods: A total of 210 participants were enrolled, including 68 with normal cognition (NC), 75 with mild cognitive impairment due to AD (AD-MCI), and 67 with dementia due to AD (AD-D). Circulating OCM biomarkers were measured, including serum folate, vitamin B12, and homocysteine levels. Glymphatic-related function was evaluated using the diffusion tensor imaging-analysis along the perivascular space (DTI-ALPS) index, and comprehensive neuropsychological assessments were performed. Results: Serum folate levels ( p = 0.020) and DTI-ALPS index ( p < 0.001) differed significantly between NC and AD groups, with more pronounced differences among female ( p = 0.005; 0.001) and late-life ( p = 0.046; 0.021) subgroups. In AD patients, folate levels were positively correlated with DTI-ALPS index ( r = 0.212, p FDR = 0.032), and both were associated with domain-specific cognitive performance. The low-risk group (high folate and high DTI-ALPS index) outperformed the high-risk group in memory ( p = 0.001) and processing speed ( p = 0.005), and showed higher MMSE ( p = 0.021) and memory scores ( p = 0.003) than the moderate-risk group. Conclusion: Lower serum folate levels and reduced DTI-ALPS index were associated with poorer cognitive performance in AD. Their co-occurrence was linked to worse cognitive outcomes. These findings suggest a potential association between metabolic status and glymphatic function in AD, which requires confirmation in longitudinal studies.
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2) , e71201
Resolving cognitive heterogeneity in white matter hyperintensities through integrated analyses of microbiome, metabolome, and brain glymphatic function
INTRODUCTION: Individuals with similar white matter hyperintensities (WMH) burden show heterogeneous cognitive outcomes, yet the biological mechanisms underlying this variability remain incompletely understood. METHODS: We integrated 16S rDNA sequencing, untargeted metabolomics, and multi‐modal magnetic resonance imaging (MRI) to comprehensively characterize gut microbiome, plasma metabolome, and brain glymphatic function in 56 healthy controls, 40 WMH with normal cognition (WMH‐NC), and 49 WMH with cognitive impairment (WMH‐CI). RESULTS: Group comparisons revealed differences in six bacterial genera, three plasma metabolites, and five glymphatic markers across three groups, with Acetivibrio , 1,5‐naphthalenediamine, beta‐uridine, free water fraction within the white matter, and index of diffusivity along the perivascular spaces (ALPS index) showing differences between WMH‐CI and WMH‐NC. Correlation and mediation analyses demonstrated associations between microbiota and cognition, mediated by tetradecyldiethanolamine and ALPS index. DISCUSSION: These findings provide preliminary insights into plausible microbiota‐metabolites‐glymphatic function‐cognition associations in WMH, potentially informing more targeted interventions for vascular cognitive impairment.
- 17 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2) , e71201
Top Cited PapersOpen AccessResolving cognitive heterogeneity in white matter hyperintensities through integrated analyses of microbiome, metabolome, and brain glymphatic function
INTRODUCTION: Individuals with similar white matter hyperintensities (WMH) burden show heterogeneous cognitive outcomes, yet the biological mechanisms underlying this variability remain incompletely understood. METHODS: We integrated 16S rDNA sequencing, untargeted metabolomics, and multi‐modal magnetic resonance imaging (MRI) to comprehensively characterize gut microbiome, plasma metabolome, and brain glymphatic function in 56 healthy controls, 40 WMH with normal cognition (WMH‐NC), and 49 WMH with cognitive impairment (WMH‐CI). RESULTS: Group comparisons revealed differences in six bacterial genera, three plasma metabolites, and five glymphatic markers across three groups, with Acetivibrio , 1,5‐naphthalenediamine, beta‐uridine, free water fraction within the white matter, and index of diffusivity along the perivascular spaces (ALPS index) showing differences between WMH‐CI and WMH‐NC. Correlation and mediation analyses demonstrated associations between microbiota and cognition, mediated by tetradecyldiethanolamine and ALPS index. DISCUSSION: These findings provide preliminary insights into plausible microbiota‐metabolites‐glymphatic function‐cognition associations in WMH, potentially informing more targeted interventions for vascular cognitive impairment.
- Open Access
- 18 January 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 49, 103951
Association of MRI indexes of glymphatic system with brain atrophy and cognitive impairment in cerebral small vessel disease
- 18 January 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 49, 103951
Open AccessAssociation of MRI indexes of glymphatic system with brain atrophy and cognitive impairment in cerebral small vessel disease
- Open Access
- 13 November 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1680094
Glymphatic system impairment in cerebral small vessel disease: associations with perivascular space volume and cognition
Objective: While emerging evidence links glymphatic dysfunction to cerebral small vessel disease (CSVD), its clinical relevance remains poorly defined. This study aimed to investigate the relationships among glymphatic function, perivascular space (PVS), and cognitive performance in CSVD. Methods: We enrolled 120 CSVD patients [52 with no cognitive impairment (CSVD-NCI) and 68 with mild cognitive impairment (CSVD-MCI)] and 40 healthy controls (HCs). Glymphatic function was assessed using the left ALPS index derived from diffusion tensor imaging analysis along the perivascular space (DTI-ALPS). Group comparisons in the ALPS index and PVS volume fraction (VF), and correlations among glymphatic function, PVS burden, and cognition were analyzed. Results: Compared to HCs, CSVD patients showed decreased ALPS index and increased PVS VF in basal ganglia (BG), caudate, putamen, and hippocampus, with more pronounced alterations in the left hemisphere. The ALPS index was inversely correlated with PVS VF in the BG ( r = −0.232, p = 0.014), thalamus ( r = −0.213, p = 0.024), caudate ( r = −0.221, p = 0.019), and putamen ( r = −0.210, p = 0.026) in CSVD. Furthermore, a lower ALPS index was associated with poorer performance in global cognition ( r = 0.312, p = 0.001), executive function ( r = 0.242, p = 0.012), processing speed ( r = 0.264, p = 0.006), and visuospatial function ( r = 0.272, p = 0.004). Finally, the ALPS index partially mediated the association between putamen-PVS VF and global cognitive function, especially in the left hemisphere. Conclusion: Our findings demonstrate that impaired glymphatic function was associated with enlarged BG-PVS, especially in the putamen, and worse cognitive performance, highlighting its potential role in disease progression and cognitive decline in CSVD.
- 13 November 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1680094
Open AccessGlymphatic system impairment in cerebral small vessel disease: associations with perivascular space volume and cognition
Objective: While emerging evidence links glymphatic dysfunction to cerebral small vessel disease (CSVD), its clinical relevance remains poorly defined. This study aimed to investigate the relationships among glymphatic function, perivascular space (PVS), and cognitive performance in CSVD. Methods: We enrolled 120 CSVD patients [52 with no cognitive impairment (CSVD-NCI) and 68 with mild cognitive impairment (CSVD-MCI)] and 40 healthy controls (HCs). Glymphatic function was assessed using the left ALPS index derived from diffusion tensor imaging analysis along the perivascular space (DTI-ALPS). Group comparisons in the ALPS index and PVS volume fraction (VF), and correlations among glymphatic function, PVS burden, and cognition were analyzed. Results: Compared to HCs, CSVD patients showed decreased ALPS index and increased PVS VF in basal ganglia (BG), caudate, putamen, and hippocampus, with more pronounced alterations in the left hemisphere. The ALPS index was inversely correlated with PVS VF in the BG ( r = −0.232, p = 0.014), thalamus ( r = −0.213, p = 0.024), caudate ( r = −0.221, p = 0.019), and putamen ( r = −0.210, p = 0.026) in CSVD. Furthermore, a lower ALPS index was associated with poorer performance in global cognition ( r = 0.312, p = 0.001), executive function ( r = 0.242, p = 0.012), processing speed ( r = 0.264, p = 0.006), and visuospatial function ( r = 0.272, p = 0.004). Finally, the ALPS index partially mediated the association between putamen-PVS VF and global cognitive function, especially in the left hemisphere. Conclusion: Our findings demonstrate that impaired glymphatic function was associated with enlarged BG-PVS, especially in the putamen, and worse cognitive performance, highlighting its potential role in disease progression and cognitive decline in CSVD.
- Open Access
- 30 August 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-14
Trends and inequalities in the global burden of alzheimer’s disease and other dementias, 1990–2021: a Chinese perspective
Given the growing global burden of Alzheimer’s Disease and Other Dementias (ADODs) and inequalities in its distribution, it is of great necessity to analyze the trends and cross-country inequalities in the burden of ADODs globally and in China from 1990 to 2021. Estimates and 95% uncertainty intervals (UIs) for incidence, prevalence, and disability-adjusted life years (DALYs) of ADODs were obtained from the Global Burden of Diseases Study (GBD) 2021. We described the epidemiology of ADODs at global, regional, and national levels, conducting temporal trend analyses using estimated annual percentage change, joinpoint regression, and age-period-cohort model. Additionally, we performed spatial autocorrelation, decomposition, and cross-country inequality analyses, comparing the burden in China to global trends. The global burden of ADODs increased overall from 1990 to 2021. GBD 2021 estimated 9,837,056 incident cases, 56,856,688 prevalent cases, and 36,332,687 DALYs for ADODs worldwide in 2021, with the highest case number in East Asia and highest age-standardized rate of DALYs in central sub-Saharan Africa. Spatial trends analyses showed hot spots in sub-Saharan Africa, the Middle East and North Africa, Europe, and High-income North America. Decomposition analysis revealed that changes in DALYs were primarily driven by population growth and aging, followed by prevalence, case fatality, and disease severity. Significant increases in absolute and relative sociodemographic index (SDI)-related inequalities in DALYs were observed from 1990 to 2021, with 318.19 to 759.97, and 0.43 to 0.49, respectively. The burden of ADODs globally and in China showed overall increasing trends from 1990 to 2021. This increase was primarily driven by population growth and aging. Countries with high SDI values faced a disproportionately large burden of dementia, and SDI-related inequalities among countries exacerbated over time. These findings highlight significant challenges for the prevention and control of ADODs globally and in China.
- 30 August 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-14
Open AccessTrends and inequalities in the global burden of alzheimer’s disease and other dementias, 1990–2021: a Chinese perspective
Given the growing global burden of Alzheimer’s Disease and Other Dementias (ADODs) and inequalities in its distribution, it is of great necessity to analyze the trends and cross-country inequalities in the burden of ADODs globally and in China from 1990 to 2021. Estimates and 95% uncertainty intervals (UIs) for incidence, prevalence, and disability-adjusted life years (DALYs) of ADODs were obtained from the Global Burden of Diseases Study (GBD) 2021. We described the epidemiology of ADODs at global, regional, and national levels, conducting temporal trend analyses using estimated annual percentage change, joinpoint regression, and age-period-cohort model. Additionally, we performed spatial autocorrelation, decomposition, and cross-country inequality analyses, comparing the burden in China to global trends. The global burden of ADODs increased overall from 1990 to 2021. GBD 2021 estimated 9,837,056 incident cases, 56,856,688 prevalent cases, and 36,332,687 DALYs for ADODs worldwide in 2021, with the highest case number in East Asia and highest age-standardized rate of DALYs in central sub-Saharan Africa. Spatial trends analyses showed hot spots in sub-Saharan Africa, the Middle East and North Africa, Europe, and High-income North America. Decomposition analysis revealed that changes in DALYs were primarily driven by population growth and aging, followed by prevalence, case fatality, and disease severity. Significant increases in absolute and relative sociodemographic index (SDI)-related inequalities in DALYs were observed from 1990 to 2021, with 318.19 to 759.97, and 0.43 to 0.49, respectively. The burden of ADODs globally and in China showed overall increasing trends from 1990 to 2021. This increase was primarily driven by population growth and aging. Countries with high SDI values faced a disproportionately large burden of dementia, and SDI-related inequalities among countries exacerbated over time. These findings highlight significant challenges for the prevention and control of ADODs globally and in China.
- Open Access
- 6 August 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1630022
Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer’s disease, with hypertensive dependency
Background: Neuroinflammation and hypertension are involved in Alzheimer’s disease (AD). However, their independent and additive impacts on astrocytes and AD-related pathologies have not been fully explored. Hence, this study investigated whether the associations between astrocyte reactivity, measured by cerebrospinal fluid (CSF), Chitinase 3-like protein 1 (CHI3L1/YKL-40), and AD-related pathologies were mediated by neuroinflammation and whether these associations were modified by hypertension. We also investigated the influence of hypertension on the relationship between baseline levels of CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Methods: This study analyzed 288 participants from the AD Neuroimaging Initiative (ADNI) database. Multivariate linear regression, interaction, and subgroup analyses were conducted to explore the interrelationship between CSF YKL-40, AD biomarkers, neuroinflammation, cognitive function, and brain structures. Causal mediation analyses with 10,000 bootstrapped iterations were performed, using CSF YKL-40 as the independent variable and AD-related pathologies as the dependent variables, to explore mediation effects of neuroinflammation. Linear mixed-effects models were employed to study the associations between CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Results: Higher baseline CSF YKL-40 levels were correlated with higher p-tau, t-tau, and neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2), but with lower entorhinal cortex volume. Interaction showed that hypertension had a moderating influence on the associations between CSF YKL-40 and p-tau and t-tau. The significant associations of CSF YKL-40 with p-tau and t-tau were partially mediated by neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2) in the whole sample (proportions: 13.0%∼78.8%). Similarly, the partial mediation effects of VCAM1, sTNFR1, and sTNFR2 on the aforementioned associations also existed in hypertensive subgroup (proportions: 17.9%∼50.3%). Additionally, higher baseline levels of CSF YKL-40 predicted faster decline in cognitive performance and brain atrophy (volumes of whole brain, hippocampus, entorhinal cortex, and middle temporal lobe) in the whole sample. Notably, subgroup analyses showed that the associations between higher CSF YKL-40 and faster brain atrophy were pronounced in hypertensive individuals.Conclusion: These findings suggest that neuroinflammation may mediate the relationship between astrocyte reactivity, measured by CSF YKL-40, and AD-related pathologies, with significant hypertensive dependency. Furthermore, elevated baseline CSF YKL-40 levels accelerated cognitive decline and brain atrophy, particularly in hypertensive individuals.
- 6 August 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1630022
Open AccessNeuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer’s disease, with hypertensive dependency
Background: Neuroinflammation and hypertension are involved in Alzheimer’s disease (AD). However, their independent and additive impacts on astrocytes and AD-related pathologies have not been fully explored. Hence, this study investigated whether the associations between astrocyte reactivity, measured by cerebrospinal fluid (CSF), Chitinase 3-like protein 1 (CHI3L1/YKL-40), and AD-related pathologies were mediated by neuroinflammation and whether these associations were modified by hypertension. We also investigated the influence of hypertension on the relationship between baseline levels of CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Methods: This study analyzed 288 participants from the AD Neuroimaging Initiative (ADNI) database. Multivariate linear regression, interaction, and subgroup analyses were conducted to explore the interrelationship between CSF YKL-40, AD biomarkers, neuroinflammation, cognitive function, and brain structures. Causal mediation analyses with 10,000 bootstrapped iterations were performed, using CSF YKL-40 as the independent variable and AD-related pathologies as the dependent variables, to explore mediation effects of neuroinflammation. Linear mixed-effects models were employed to study the associations between CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Results: Higher baseline CSF YKL-40 levels were correlated with higher p-tau, t-tau, and neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2), but with lower entorhinal cortex volume. Interaction showed that hypertension had a moderating influence on the associations between CSF YKL-40 and p-tau and t-tau. The significant associations of CSF YKL-40 with p-tau and t-tau were partially mediated by neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2) in the whole sample (proportions: 13.0%∼78.8%). Similarly, the partial mediation effects of VCAM1, sTNFR1, and sTNFR2 on the aforementioned associations also existed in hypertensive subgroup (proportions: 17.9%∼50.3%). Additionally, higher baseline levels of CSF YKL-40 predicted faster decline in cognitive performance and brain atrophy (volumes of whole brain, hippocampus, entorhinal cortex, and middle temporal lobe) in the whole sample. Notably, subgroup analyses showed that the associations between higher CSF YKL-40 and faster brain atrophy were pronounced in hypertensive individuals.Conclusion: These findings suggest that neuroinflammation may mediate the relationship between astrocyte reactivity, measured by CSF YKL-40, and AD-related pathologies, with significant hypertensive dependency. Furthermore, elevated baseline CSF YKL-40 levels accelerated cognitive decline and brain atrophy, particularly in hypertensive individuals.